Here's How Dr Reddy's Aims To Drive Growth In India Market
India remains a pivotal market for Dr Reddy's Laboratories Ltd., MV Ramana, chief executive officer of branded markets (India and emerging Markets) said, as he outlined three primary levers guiding its focused strategy aimed at driving growth.
Firstly, the pharmaceutical company is committed to expanding its base business, leveraging its portfolio of strong brands and established market acceptance to maintain and strengthen its position in the Indian market, Ramana told NDTV Profit's Sajeet Manghat in an interview.
Dr Reddy's is actively pursuing innovation across multiple fronts, including the development of innovative assets, consumer health products and digital therapeutics. Thirdly, the drugmaker is exploring inorganic opportunities to address portfolio gaps and enhance its presence in chronic disease management.

MV Ramana (Source: Dr. Reddy's Laboratories Ltd. website)
While the exact impact on sales for the current financial year remains uncertain, Ramana emphasises the company's confidence, supported by its strong cash position. "We would continue to look for opportunities that are meaningful with the right value and where we could add our synergies to the business," he said.
Capex Plans
Ramana pointed out that there are capital-expenditure initiatives scheduled for fiscal 2025–26. He said the primary focus during this period would be on product launches and identifying areas where additional capex is needed to support these launches.
The pharmaceutical company's net profit jumped 36% to Rs 1,310 crore in the fourth quarter of fiscal 2024, beating analysts' estimates of Rs 1,215 crore.
Dr Reddy's Q4 Earnings Highlights (Consolidated, YoY)
Net profit up 36% to Rs 1,310 crore versus Rs 960 crore (Bloomberg estimate: Rs 1,215 crore).
Revenue up 13% to Rs 7,114 crore versus Rs 6,315.2 crore (Bloomberg estimate: Rs 7,027 crore).
Ebitda up 19% to Rs 1,831 crore versus Rs 1,534 crore (Bloomberg estimate: Rs 1,810 crore).
Margin expands to 25.7% versus 24.3% (Bloomberg estimate: 25.8%).
Here's What Brokerages Say
Nuvama Institutional Research
Nuvama retains 'reduce' on Dr Reddy's with a target price of Rs 5,028 apiece.
The core business Ebitda margin, excluding gRevlimid, corrected 200–300 basis points year-on-year to 17%, implying weakness in base profitability.
The company's complex product research and development, coupled with weakness in the domestic business, may keep base profitability tepid, while growth initiatives would kick in beyond fiscal 2027.
Motilal Oswal Financial Services
Motilal maintains a 'neutral' rating on the stock with a target price of Rs 6,070 apiece.
After delivering a 30% year-on-year earnings growth in fiscal 2024, Motilal expects earnings growth to moderate to a 3.5% compound annual growth rate over fiscal 2024–26, partly due to a gradual build-up of market share of g-Revlimid.
The investment in the joint venture with Nestle and in the biosimilar segment should drive commercial benefits after fiscal 2026.
The valuation adequately factors in the upside in earnings.
Shares of Dr Reddy's fell as much as 4.87% during the day to Rs 5,952.70 apiece on the NSE. It was trading 3.41% lower at Rs 6,044 per share, compared to a 0.0.8% advance in the benchmark Nifty at 11:48 a.m.
The stock has risen 4.23% on a year-to-date basis and 1.98% in the last 12 months. The total traded volume so far in the day stood at 4.7 times its 30-day average. The relative strength index was at 43.34.
Fifteen out of the 40 analysts tracking the company have a 'buy' rating on the stock, 11 recommend 'hold' and 14 suggest 'sell', according to Bloomberg data. The average of 12-month analyst price targets implies a potential upside of 2.8%.
Watch The Interview Here
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.